Targeting protein kinase C: New therapeutic opportunities against high-grade malignant gliomas?

Oncologist

Volumn 7, Issue 1, 2002, Pages 17-33

  Da Rocha, A B ^a   Mans, D R A ^a   Regner, A ^a   Schwartsmann, G ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Cell invasion; Cell proliferation; Extracellular signal regulated kinases; High grade malignant gliomas; Intracellular signaling; Mitogen activated protein kinase extracellular signal regulated kinase; Ornithine decarboxylase; Protein kinase C

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 7 HYDROXYSTAUROSPORINE; ALTEPLASE; BRYOSTATIN 1; CALPHOSTIN C; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MIDOSTAURIN; ORNITHINE DECARBOXYLASE; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; RAF PROTEIN; RAS PROTEIN; SAFINGOL; STAUROSPORINE; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANTINEOPLASTIC ACTIVITY; CANCER GRADING; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; ENZYME INHIBITION; GENE MUTATION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CHILD; CHILD, PRESCHOOL; ENZYME ACTIVATION; ENZYME INHIBITORS; GLIOMA; HUMANS; INFANT; LACTONES; MACROLIDES; MUTATION; NAPHTHALENES; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PHENOTYPE; PROTEIN KINASE C; SPHINGOSINE; STAUROSPORINE;

EID: 0036177115     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-1-17     Document Type: Review

References (183)

1. Brain tumors
2. Genetics of glioma progression and the definition of primary and secondary glioblastoma
3. Chemotherapy of primary brain tumors
4. Complications and expected outcome of glioma surgery
5. Clinical results of unconventional fractionation radiotherapy in central nervous system tumors
6. Expression pattern of chemoresistance-related genes in human malignant brain tumors: A working knowledge for proper selection of anticancer drugs
7. Molecular mechanisms of mutagenesis and multistage carcinogenesis
8. Molecular biology of central nervous system neoplasms
9. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma
10. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
11. Novel anticancer drug discovery
12. A NCNSC phase II trial of thalidomide, an antiangiogenic agent, in patients with recurrent malignant gliomas
13. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
14. Effects of protein kinase C modulators on multidrug resistance in human glioma cells
15. 6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma
16. Ongoing trials with matrix metalloproteinase inhibitors
17. Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro
18. The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to antiglioma therapy
19. Overexpression of protein kinase C epsilon in astroglial brain tumor-derived cell lines and primary tumor samples
20. The role of protein kinase C isoforms in cell proliferation and apoptosis
21. The extended protein kinase C superfamily
22. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C
23. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C
24. Signaling through protein kinase C
25. Signal perception and transduction: The role of protein kinases
26. Platelet-derived growth factor activates protein kinase C epsilon through redundant and independent signaling pathways involving phospholipase C gamma or phosphatidylinositol 3-kinase
27. Phosphorylation of protein kinase Calpha on serine 657 controls the accumulation of active enzyme and contributes to its phosphatase-resistant state
28. Phosphorylation at conserved carboxyl-terminal hydrophobic motif regulates the catalytic and regulatory domains of protein kinase C
29. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes
30. Protein kinase C δ activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf
31. Protein kinase C epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity
32. Inactivation of Bcl-2 by phosphorylation
33. Raf meets Ras: Completing the framework of a signal transduction pathway
34. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: A new therapeutic strategy
35. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation
36. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes
37. Age-dependent expression of protein kinase C isoforms in rat islets
38. The occurrence of three calcium-independent protein kinase C subspecies (δ, ε and) in retina of different species
39. Isolation of protein kinase C-alpha-regulated cDNAs associated with breast tumor aggressiveness by differential mRNA display
40. Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells
41. Anti-proliferative activity of protein kinase C in apical compartments of human colonic crypts: Evidence for a less activated protein kinase C in small adenomas
42. Overexpression of protein kinase C alpha in MCF-10A human breast cells engenders dramatic alterations in morphology, proliferation, and motility
43. An N-myristoylated protein kinase C-alpha pseudosubstrate peptide that functions as a multidrug resistance reversal agent in human breast cancer cells is not a P-glycoprotein substrate
44. Protein kinase C alpha and protein kinase C delta play opposite roles in the proliferation and apoptosis of glioma cells
45. PKC-delta is an apoptotic lamin kinase
46. Critical targets of protein kinase C in differentiation of tumour cells
47. Tumor promotion by depleting cells of protein kinase C delta
48. Overexpression of PKC epsilon in R6 fibroblasts causes increased production of active TGFbeta
49. Protein kinase C epsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway
50. Mitogenic signaling by substance P and bombesin-like neuropeptide receptors in astrocytic/glial brain tumor-derived cell lines
51. Protein kinase C-epsilon transgenic mice: A unique model for metastatic squamous cell carcinoma
52. Differential sensitivity of breast cancer cells to tumor necrosis factor-alpha: Involvement of protein kinase C
53. Taxonomy and function of C1 protein kinase C homology domains
54. Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester
55. Extending the C2 domain family: C2s in PKCs delta, epsilon, zeta, theta, phospholipases, GAPs, and perforin
56. Identification of intracellular receptor proteins for activated protein kinase C
57. C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo
58. Modulation of PKC in antitumor treatment
59. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells
60. The protein kinase Crelated PKC-L(eta) gene product is localized in the cell nucleus
61. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity
62. Regulation of phosphoinositide-specific phospholipase C
63. Signalling through phosphoinositide 3-kinases: The lipids take centre stage
64. Phospholipase D is associated in a phorbol ester-dependent manner with protein kinase C-alpha and with a 220-kDa protein which is phosphorylated on serine and threonine
65. Protein kinase C and lipid signaling for sustained cellular responses
66. The MAPK signaling cascade
67. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C
68. Cell transformation, invasion, and angiogenesis: A regulatory role for ornithine decarboxylase and polyamines?
69. Polyamine metabolism in gliomas
70. Ornithine decarboxylase activity is critical for cell transformation
71. Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase
72. Ornithine decarboxylase: An indicator for growth of NIH 3T3 fibroblasts and their c-Ha-ras transformants
73. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix
74. Protein kinase C-mediated in vitro invasion of human glioma cells through extracelIular-signal-regulated kinase and ornithine decarboxylase
75. Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes
76. Two closely related isoforms of protein kinase C produce reciprocal effects on the growth of rat fibroblasts. Possible molecular mechanisms
77. Long chain diamines inhibit growth of C6 glioma cells according to their hydrophobicity. An in vitro and molecular modeling study
78. Protein kinase C and growth regulation of malignant gliomas
79. Protein kinase C in cultured adult human oligodendrocytes: A potential role for isoform α as a mediator of process outgrowth
80. Selective translocation of protein kinase C-8 in PC12 cells during nerve growth factor-induced neuritogenesis
81. Therapeutic potential of protein kinase C inhibitors
82. Bryostatin I, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin
83. The catalytic domain of protein kinase Cdelta confers protection from down-regulation induced by bryostatin 1
84. Pharmacology and clinical experience with bryostatin 1: A novel anticancer drug
85. Phase Ib trial of bryostatin 1 in patients with refractory malignancies
86. A phase I trial of bryostatin I in children with refractory solid tumors: A Pediatric Oncology Group study
87. Phase II evaluation of bryostatin-1 in metastatic melanoma
88. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
89. The pharmacology and clinical uses of tamoxifen
90. Effects of TGF β on normal and malignant mammary epithelium
91. Inhibition of protein kinase C by tamoxifen
92. Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity
93. Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitizes cultured human glioblastoma cells not to etoposide but to γ-radiation and BCNU
94. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro
95. Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen
96. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen
97. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood
98. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas
99. Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients
100. High-dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: A phase IB study
101. Tamoxifen and carboplatin combinational treatment of high-grade gliomas: Results of a clinical trial on newly diagnosed patients
102. Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: A phase II study
103. Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: Results of a Brazilian cooperative study
104. Procarbazine and highdose tamoxifen as a second-line regimen in recurrent high-grade gliomas: A phase II study
105. High-dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma
106. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin
107. 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs
108. Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase
109. Staurosporine differentially inhibits glioma versus non-glioma cell lines
110. UCN-01, a selective inhibitor of protein kinase C from Strepromyces
111. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity
112. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models
113. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent
114. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue
115. Differential inhibition of cytosolic and membrane-derived protein kinase C activity by staurosporine and other kinase inhibitors
116. 2 checkpoint function in cancer cells with disrupted p53
117. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
118. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines
119. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation
120. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies
121. Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity
122. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
123. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance
124. Calphostins (UCN1028), novel and specific inhibitors of protein kinase C. I. Fermentation, isolation, physico-chemical properties and biological activities
125. Calphostin C (UCN-1028C),a novel microbial compound,is a highly potent and specific inhibitor of protein kinase C
126. Inhibition of protein kinase C by calphostin C is light-dependent
127. Potent and specific inhibitors of protein kinase C of microbial origin
128. Potent direct inhibition of mammalian phospholipase D isoenzymes by calphostin-C Biochemistry
129. The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro
130. Activated calphostin C cytotoxicity is independent of p53 status and in vivo metastatic potential
131. Antisense oligonucleotide inhibition of serine/threonine kinases: An innovative approach to cancer treatment
132. Antisense approaches for the treatment of cancer
133. Identification of PKC-isoformspecific biological actions using pharmacological approaches
134. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
135. Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2′-O-propyl modifications
136. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
137. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
138. Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway
139. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines
140. Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor
141. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro
142. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C
143. Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation
144. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro
145. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promotor
146. Protein kinase C-mediated regulation of the cell cycle
147. Inhibition of protein kinase C (PKC) activity by tamoxifen (Tmx) in cultured human glioma cells
148. Protein kinase C targeting in antineoplastic treatment strategies
149. Protein kinase C modulation and anticancer drug response
150. Combined hormonal and chemotherapy treatment of recurrent high-grade astrocytoma
151. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
152. ECM-mediated glioma cell invasion
153. Cellular and molecular mechanisms of tumor invasion
154. Extracellular matrix remodeling during morphogenesis
155. Embryo implantation and tumor metastasis: Common pathways of invasion and angiogenesis
156. Matrix metalloproteinases and diseases of the CNS
157. Matrix metalloproteinases and their biological function in human gliomas
158. Matrix metalloproteinases: Biologic activity and clinical implications
159. Dissecting glioma invasion: Interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype
160. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter
161. Regulation of matrix metalloproteinase expression in tumor invasion
162. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro
163. Proteases and their inhibitors in human brain tumours: A review
164. Matrix metalloproteinase inhibitors
165. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer
166. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
167. Glioma invasion in vitro: Regulation by matrix metalloprotease-2 and protein kinase C
168. The role of protein kinase C alpha in U-87 glioma invasion
169. Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells
170. Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle progression
171. Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells
172. Protein kinases C (PKCs) α and ε cooperate with the epidermal growth factor receptor (EGFR) in the induction of ornithine decarboxylase (ODC) mRNA expression in cultured human glioma cells
173. The identification of four protein kinase C isoforms in human glioblastoma cell lines: PKC alpha, gamma, epsilon, and zeta
174. Diacylglycerol kinase is phosphorylated in vivo upon stimulation of the epidermal growth factor receptor and serine/threonine kinases including protein kinase C-epsilon
175. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
176. PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase
177. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase
178. Omithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: Cellular transformation and invasion
179. PKC alpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic
180. Role of the alpha1 and alpha2 integrin cytoplasmic domains in cell morphology, motility and responsiveness to stimulation by the protein kinase C pathway
181. Overexpression of protein kinase C alpha in MCF-7 breast cancer cells results in differential regulation and expression of alphavbeta3 and alphavbeta5
182. Apoptosis is induced in glioma cells by antisense oligonucleotides to protein kinase C alpha and is enhanced by cycloheximide
183. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Cα antisense oligonucleotide